These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23811804)

  • 21. Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding.
    Costa I; Pajon R; Granoff DM
    mBio; 2014 Aug; 5(5):e01625-14. PubMed ID: 25161192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.
    Gossger N; Snape MD; Yu LM; Finn A; Bona G; Esposito S; Principi N; Diez-Domingo J; Sokal E; Becker B; Kieninger D; Prymula R; Dull P; Ypma E; Toneatto D; Kimura A; Pollard AJ;
    JAMA; 2012 Feb; 307(6):573-82. PubMed ID: 22318278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial.
    Martinón-Torres F; Carmona Martinez A; Simkó R; Infante Marquez P; Arimany JL; Gimenez-Sanchez F; Couceiro Gianzo JA; Kovács É; Rojo P; Wang H; Bhusal C; Toneatto D
    J Infect; 2018 Mar; 76(3):258-269. PubMed ID: 29253560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children.
    Vesikari T; Prymula R; Merrall E; Kohl I; Toneatto D; Dull PM
    Vaccine; 2015 Jul; 33(32):3850-8. PubMed ID: 26141011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy.
    Fazio C; Biolchi A; Neri A; Tomei S; Vacca P; Ambrosio L; Palmieri A; Mori E; La Gaetana R; Pizza M; Giuliani MM; Serino L; Stefanelli P
    Hum Vaccin Immunother; 2021 Jul; 17(7):2225-2231. PubMed ID: 33522380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules.
    Sadarangani M; Sell T; Iro MA; Snape MD; Voysey M; Finn A; Heath PT; Bona G; Esposito S; Diez-Domingo J; Prymula R; Odueyungbo A; Toneatto D; Pollard AJ;
    CMAJ; 2017 Oct; 189(41):E1276-E1285. PubMed ID: 29038320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination.
    Block SL; Christensen S; Verma B; Xie F; Keshavan P; Dull PM; Smolenov I
    Vaccine; 2015 Apr; 33(18):2175-82. PubMed ID: 25744224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II).
    Esposito S; Prymula R; Zuccotti GV; Xie F; Barone M; Dull PM; Toneatto D
    Hum Vaccin Immunother; 2014; 10(7):2005-14. PubMed ID: 25424810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults.
    Martinón-Torres F; Nolan T; Toneatto D; Banzhoff A
    Hum Vaccin Immunother; 2019; 15(12):2940-2951. PubMed ID: 31246520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.
    Biolchi A; Tomei S; Santini L; Welsch JA; Toneatto D; Gaitatzis N; Bai X; Borrow R; Giuliani MM; Mori E; Pizza M
    Hum Vaccin Immunother; 2019; 15(3):725-731. PubMed ID: 30352000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB.
    Abad R; Biolchi A; Moschioni M; Giuliani MM; Pizza M; Vázquez JA
    Clin Vaccine Immunol; 2015 Apr; 22(4):357-60. PubMed ID: 25630407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.
    Flacco ME; Manzoli L; Rosso A; Marzuillo C; Bergamini M; Stefanati A; Cultrera R; Villari P; Ricciardi W; Ioannidis JPA; Contopoulos-Ioannidis DG
    Lancet Infect Dis; 2018 Apr; 18(4):461-472. PubMed ID: 29371070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.
    Vesikari T; Esposito S; Prymula R; Ypma E; Kohl I; Toneatto D; Dull P; Kimura A;
    Lancet; 2013 Mar; 381(9869):825-35. PubMed ID: 23324563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
    Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
    Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.
    McQuaid F; Snape MD; John TM; Kelly S; Robinson H; Houlden J; Voysey M; Toneatto D; Kitte C; Dull PM; Pollard AJ
    Pediatr Infect Dis J; 2014 Jul; 33(7):760-6. PubMed ID: 24722351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269.
    Stella M; Giuliani M; Biolchi A; Tomei S; De Paola R; Bai X; Borrow R; Lucidarme J; La Gaetana R; Toneatto D; Pizza M; Serino L; Mori E; Giuliani MM
    Hum Vaccin Immunother; 2020 Apr; 16(4):945-948. PubMed ID: 31770063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine.
    Granoff DM; Costa I; Konar M; Giuntini S; Van Rompay KK; Beernink PT
    J Infect Dis; 2015 Sep; 212(5):784-92. PubMed ID: 25676468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.